Use of the CRISPR/Cas9-based epigenetic gene activation system In Vivo: A new potential therapeutic modality

Research output: Contribution to journal › Article

Cite this

@article{06bf824cb8394672bd8a3fd036510a95,

title = "Use of the CRISPR/Cas9-based epigenetic gene activation system In Vivo: A new potential therapeutic modality",

author = "Ibrahim, {Samar C} and Robertson, {Keith D}",

year = "2018",

month = sep,

day = "1",

doi = "10.1002/hep.29860",

language = "English (US)",

volume = "68",

pages = "1191--1193",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Use of the CRISPR/Cas9-based epigenetic gene activation system In Vivo

T2 - A new potential therapeutic modality

AU - Ibrahim, Samar C

AU - Robertson, Keith D

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85047525907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047525907&partnerID=8YFLogxK

U2 - 10.1002/hep.29860

DO - 10.1002/hep.29860

M3 - Article

C2 - 29489018

AN - SCOPUS:85047525907

VL - 68

SP - 1191

EP - 1193

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -